

Study: ENGOT-ov76 / GLORIOSA

Randomized, multicenter, open-label, Phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FR α -high recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers who have not progressed after second-line platinum-based chemotherapy plus bevacizumab (GLORIOSA).

MaNGO Sites:

Prov	City	Site	Principal Investigator	Active
FI	Firenze	Ospedale Careggi	Maria Cristina Petrella*	Yes
GE	Genova	Ospedale San Martino	Serafina Mammoliti	Yes
LC	Lecco	Ospedale Manzoni	Federica Villa	Yes
LU	Lucca	Ospedale San Luca	Editta Baldini	Yes
MI	Milano	Istituto Nazionale dei Tumori	Francesco Raspagliesi	Yes
PC	Piacenza	Osp. Guglielmo da Saliceto	Rosa Porzio	Yes
PR	Parma	AOU Parma	Angelica Sikokis	Yes
RE	Reggio Emilia	Arcispedale S. Maria Nuova	Alessandra Bologna	Yes
RM	Roma	Ospedale Umberto I	Federica Tomao	Yes

* MaNGO Principal Investigator